ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 750,25
0,40%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Elicio Therapeutics Inc (ELTX)

  7. Elicio Therapeutics Inc (ELTX) Actualités

ELTX

Elicio Therapeutics (ELTX)

Elicio Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ELTX
DateHeureSourceTitreSymboleSociété
23/05/202423h30GlobeNewswire Inc.Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
15/05/202422h34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELTXElicio Therapeutics Inc
15/05/202422h30GlobeNewswire Inc.Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
25/04/202414h30GlobeNewswire Inc.Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
05/04/202422h30GlobeNewswire Inc.Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
29/03/202413h30GlobeNewswire Inc.Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
18/03/202413h00GlobeNewswire Inc.Elicio Therapeutics Announces $6.0 Million Private Placement FinancingNASDAQ:ELTXElicio Therapeutics Inc
05/02/202414h30GlobeNewswire Inc.Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ELTXElicio Therapeutics Inc
25/01/202415h00GlobeNewswire Inc.Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid TumorsNASDAQ:ELTXElicio Therapeutics Inc
17/01/202414h30GlobeNewswire Inc.Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI SymposiumNASDAQ:ELTXElicio Therapeutics Inc
16/01/202414h30GlobeNewswire Inc.Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:ELTXElicio Therapeutics Inc
11/01/202414h30GlobeNewswire Inc.Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer StudyNASDAQ:ELTXElicio Therapeutics Inc
09/01/202412h00GlobeNewswire Inc.Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002NASDAQ:ELTXElicio Therapeutics Inc
22/12/202315h00GlobeNewswire Inc.Elicio Therapeutics Announces $7.0 Million Private Placement FinancingNASDAQ:ELTXElicio Therapeutics Inc
04/12/202314h00GlobeNewswire Inc.Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNASDAQ:ELTXElicio Therapeutics Inc
09/11/202322h30GlobeNewswire Inc.Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
03/11/202321h30GlobeNewswire Inc.Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
11/10/202314h00GlobeNewswire Inc.Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
27/09/202323h30GlobeNewswire Inc.Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic CancerNASDAQ:ELTXElicio Therapeutics Inc
07/09/202314h00GlobeNewswire Inc.Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer VaccinesNASDAQ:ELTXElicio Therapeutics Inc
06/09/202314h00GlobeNewswire Inc.Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:ELTXElicio Therapeutics Inc
05/09/202314h00GlobeNewswire Inc.Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic CancerNASDAQ:ELTXElicio Therapeutics Inc
28/08/202314h00GlobeNewswire Inc.Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of BiometricsNASDAQ:ELTXElicio Therapeutics Inc
22/08/202322h30GlobeNewswire Inc.Elicio Therapeutics Reports Inducement GrantsNASDAQ:ELTXElicio Therapeutics Inc
11/08/202314h30GlobeNewswire Inc.Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
09/08/202314h00GlobeNewswire Inc.Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease ModelNASDAQ:ELTXElicio Therapeutics Inc
06/06/202314h00GlobeNewswire Inc.Elicio Therapeutics Completes Reverse Merger and Provides a Corporate UpdateNASDAQ:ELTXElicio Therapeutics Inc
05/06/202323h26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ELTXElicio Therapeutics Inc
05/06/202323h09Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ELTXElicio Therapeutics Inc
05/06/202314h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ELTXElicio Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ELTX

Dernières Valeurs Consultées

NYSE
MRK
Merck
EU
BEL20
Bel 20
EU
BN
Danone
EU
HO
Thales
EU
VIV
Vivendi
NYSE
NKE
Nike
EU
DG
Vinci
EU
ACA
Credit Agricole
EU
MC
Lvmh Moet Hennessy Louis...
NASDAQ
NVDA
NVIDIA
EU
ML
Michelin
EU
RI
Pernod Ricard
EU
VK
Vallourec
EU
BNP
BNP Paribas
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés